Profound Medical Corp.PRN.TO

Health Care · Health Care Equipment & Services · TSX · Canada · profoundmedical.com

Profound Medical Corp. is a commercial-stage medical device company that develops and commercializes incision-free therapeutic systems for image-guided ablation of diseased tissue. Its flagship TULSA-PRO system combines MRI, robotically-driven transurethral ultrasound, and real-time thermal feedback to ablate prostate tissue in a single outpatient session, while its Sonalleve system uses MRI-guided focused ultrasound to treat uterine fibroids and bone metastases.

Key ratios

FCF / Sales

-238.4%TTM

2025 -238.4%2024 -219.6%2023 -314.1%

Net margin

-264.4%TTM

2025 -264.4%2024 -260.5%

ROA

-34.9%TTM

2025 -34.9%2024 -36.2%2023 -33.1%

ROE

-67.1%TTM

2025 -67.1%2024 -60.7%2023 -68.1%

Recent news

Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference 2026-09-03 · GlobeNewswire Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President 2026-09-01 · GlobeNewswire Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full 'TULSA Days' 2026-08-17 · GlobeNewswire Profound Medical Announces Management Change 2026-08-14 · GlobeNewswire Profound Medical Launches 'Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey 2026-08-13 · GlobeNewswire Profound Medical Reports Second Quarter 2026 Financial Results 2026-08-06 · GlobeNewswire Robotic Radical Prostatectomy Comes Up 'Short' in CAPTAIN Trial 2026-07-24 · GlobeNewswire Profound Medical Reports Strong First Quarter 2026 Financial Results 2026-05-07 · GlobeNewswire

Track PRN.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer